Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Shenqi Fuzheng injection (SFI) is a commonly used anti-cancer Chinese patent medicine and has long been prescribed as adjunctive treatment to platinum-based chemotherapy (PBC) in patients with stage III/IV non-small cell lung cancer (NSCLC). However, the efficacy and safety of this combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hongwei, Yao, Xiaojun, Liu, Zhengtang, Li, Ting, Xu, Cong, Wang, Jue, Sui, Xinbing, Leung, Elaine Lai-Han, Wu, Qibiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775431/
https://www.ncbi.nlm.nih.gov/pubmed/31574877
http://dx.doi.org/10.1097/MD.0000000000017350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775431/
https://www.ncbi.nlm.nih.gov/pubmed/31574877
http://dx.doi.org/10.1097/MD.0000000000017350

Ejemplares similares